Summary

243.89 5.99(2.52%)09/13/2024
Alexander`s Inc. (ALX)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
2.526.2612.1013.7016.0628.46-7.669,734.27


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close243.89
Open240.38
High245.00
Low240.38
Volume8,269
Change5.99
Change %2.52
Avg Volume (20 Days)10,251
Volume/Avg Volume (20 Days) Ratio0.81
52 Week Range162.50 - 245.00
Price vs 52 Week High-0.45%
Price vs 52 Week Low50.09%
Range1.46
Gap Up/Down-1.11
Fundamentals
Market Capitalization (Mln)1,249
EBIDTA125,431,000
PE Ratio10.6724
PEG Ratio0.0000
WallStreet Target Price160.00
Book Value45.0610
Earnings Per Share20.9100
EPS Estimate Current Quarter0.0000
EPS Estimate Next Quarter0.0000
EPS Estimate Current Year0.0000
EPS Estimate Next Year0.0000
Diluted EPS (TTM)20.9100
Revenues
Profit Marging0.4597
Operating Marging (TTM)0.4101
Return on asset (TTM)0.0409
Return on equity (TTM)0.4757
Revenue TTM233,418,000
Revenue per share TTM45.4990
Quarterly Revenue Growth (YOY)0.1600
Quarterly Earnings Growth (YOY)0.4340
Gross Profit (TTM)115,368,000
Dividends
Dividend Share18.0000
Dividend Yield0.0807
Valuations
Trailing PE10.6724
Forward PE0.0000
Price Sales (TTM)0.0000
Price Book (MRQ)4.6554
Revenue Enterprise Value 7.4105
EBITDA Enterprise Value8.5354
Shares
Shares Outstanding5,107,290
Shares Float2,125,246
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.03
Insider (%)58.39
Institutions (%)32.36


09/13 05:50 EST - zacks.com
Best Income Stocks to Buy for September 13th
BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.
09/11 22:36 EST - seekingalpha.com
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.
09/05 08:00 EST - newsfilecorp.com
Greenridge Exploration Announces Letter of Intent to Acquire ALX Resources Corp.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - September 5, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3) ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a non-binding letter of intent ("LOI") dated September 4, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Proposed Transaction"). The Proposed Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in 15 uranium exploration projects that total approximately 276,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake.
08/26 07:30 EST - newsfilecorp.com
ALX Resources Corp. Completes Prospecting and Sampling Programs at the Cannon Copper Project, Ontario
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that it has completed reconnaissance prospecting and sampling programs (the "Programs") on its 100%-owned Cannon Copper Project ("Cannon Copper" or the "Project") located in Kamichisitit Township approximately 35 kilometres (23 miles) northwest of Elliot Lake, Ontario, Canada. The Project hosts the site of the historic Cannon Copper Mine and Mill, which saw limited copper mining and processing in the late 1960s and early 1970s.
08/23 19:26 EST - zacks.com
3 Highly Ranked REITs to Buy with Rate Cuts Ahead
With the possibility of multiple rate cuts back on the table this year, Real Estate Investment Trusts (REITs) may stand to benefit the most as these equities rely on debt to finance their operations and acquire properties.
08/22 13:00 EST - zacks.com
Alexander's (ALX) Upgraded to Strong Buy: Here's What You Should Know
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
08/09 10:05 EST - zacks.com
Best Income Stocks to Buy for August 9th
NREF, DKL and ALX made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 9, 2024.
08/06 16:01 EST - globenewswire.com
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D.
08/05 10:55 EST - zacks.com
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.31 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.55 per share a year ago.
08/05 08:56 EST - globenewswire.com
Alexander's Announces Second Quarter Financial Results
PARAMUS, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2024 today and reported:
08/02 08:30 EST - seekingalpha.com
7 Potential Mousetrap REITs - High, Potentially Unsafe Yields
From a fundamental standpoint, this may be a good time to invest in REITs with high yields. It's crucial to avoid mousetrap REITs with high dividend yields that may be unsustainable, as dividend cuts quickly lead to dramatic losses in share value and reduced income. This article lists 22 equity REITs in significant danger of a dividend cut within the next 12 months.
07/31 16:01 EST - globenewswire.com
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
07/31 13:32 EST - globenewswire.com
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
PARAMUS, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 30, 2024 to stockholders of record on August 12, 2024.
07/31 05:30 EST - globenewswire.com
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
07/23 14:53 EST - globenewswire.com
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 5, 2024, before the New York Stock Exchange opens.
07/16 09:10 EST - seekingalpha.com
Alexander's Inc.:  Numerous Signs Of Distress
Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of office and retail properties in New York City, facing heavy indebtedness, shrinking revenues, and reliance on a single tenant. ALX faces liquidity issues, and may need to cut dividends or dilutively issue new shares, making it a risky investment for the longer term.
06/27 08:00 EST - seekingalpha.com
Three Office REITs To Sell With Weak Balance Sheets
There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer the most damage in any downturn. This article focuses on three specific REITs that may be particularly vulnerable in a downturn.
06/27 04:13 EST - seekingalpha.com
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
06/25 07:30 EST - newsfilecorp.com
ALX Resources Corp. Acquires Blackbird Project in Northern Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company")  is pleased to announce that it has acquired the Blackbird Project ("Blackbird", or the "Project") in northern Saskatchewan, Canada. Blackbird consists of twelve mineral claims staked in June 2024 on behalf of the Company, giving the Project a total area of approximately 11,628 hectares (28,733 acres).
06/13 07:30 EST - newsfilecorp.com
ALX Resources Corp. Receives Analytical Results from the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of the 2024 winter drilling program and upcoming summer 2024 exploration plans at its Gibbons Creek Uranium Project ("Gibbons Creek", or the "Project") located in the northern Athabasca Basin near the community of Stony Rapids, Saskatchewan. Gibbons Creek is the subject of an option earn-in transaction with Trinex Lithium Ltd.